RECIP 1.0 + PSA for response assessment in mCRPC patients treated with Ac / Lu PSMA combination therapy.

Background: Targeted alpha therapy (TAT) with Ac has shown promising results in metastatic castration-resistant prostate cancer (mCRPC) patients pre-treated with [Lu]Lu-PSMA radioligand therapy (RLT). A combination treatment regimen adding Lu to decreased Ac activities may improve toxicity profile while maintaining sufficient anti-tumor effect. We therefore evaluated clinical and image-based response parameters in patients treated with Ac-/Lu-PSMA combination therapies (ALCT).